<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>gastroenterology</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>gastroenterology | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Trans-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease
Authors: Yang, G.; Mason, A.; Gill, D.; Schooling, C. M.; Burgess, S.
Score: 5.9, Published: 2023-09-27 DOI: 10.1101/2023.09.27.23296205
Structured abstractO_ST_ABSBackgroundC_ST_ABSPlasma low-density lipoprotein (LDL)-cholesterol is positively associated with coronary artery disease risk while biliary cholesterol promotes gallstone formation. ObjectivesWe tested the hypothesis that different plasma LDL-cholesterol lowering pathways have distinct effects on biliary cholesterol and thereby risk of gallstone disease.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/gastroenterology/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="gastroenterology" />
<meta property="og:description" content="Trans-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease
Authors: Yang, G.; Mason, A.; Gill, D.; Schooling, C. M.; Burgess, S.
Score: 5.9, Published: 2023-09-27 DOI: 10.1101/2023.09.27.23296205
Structured abstractO_ST_ABSBackgroundC_ST_ABSPlasma low-density lipoprotein (LDL)-cholesterol is positively associated with coronary artery disease risk while biliary cholesterol promotes gallstone formation. ObjectivesWe tested the hypothesis that different plasma LDL-cholesterol lowering pathways have distinct effects on biliary cholesterol and thereby risk of gallstone disease." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/gastroenterology/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-10-04T10:39:33+00:00" />
<meta property="article:modified_time" content="2023-10-04T10:39:33+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="gastroenterology"/>
<meta name="twitter:description" content="Trans-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease
Authors: Yang, G.; Mason, A.; Gill, D.; Schooling, C. M.; Burgess, S.
Score: 5.9, Published: 2023-09-27 DOI: 10.1101/2023.09.27.23296205
Structured abstractO_ST_ABSBackgroundC_ST_ABSPlasma low-density lipoprotein (LDL)-cholesterol is positively associated with coronary artery disease risk while biliary cholesterol promotes gallstone formation. ObjectivesWe tested the hypothesis that different plasma LDL-cholesterol lowering pathways have distinct effects on biliary cholesterol and thereby risk of gallstone disease."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "gastroenterology",
      "item": "https://trxiv.yorks0n.com/posts/gastroenterology/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "gastroenterology",
  "name": "gastroenterology",
  "description": "Trans-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease\nAuthors: Yang, G.; Mason, A.; Gill, D.; Schooling, C. M.; Burgess, S.\nScore: 5.9, Published: 2023-09-27 DOI: 10.1101/2023.09.27.23296205\nStructured abstractO_ST_ABSBackgroundC_ST_ABSPlasma low-density lipoprotein (LDL)-cholesterol is positively associated with coronary artery disease risk while biliary cholesterol promotes gallstone formation. ObjectivesWe tested the hypothesis that different plasma LDL-cholesterol lowering pathways have distinct effects on biliary cholesterol and thereby risk of gallstone disease.",
  "keywords": [
    
  ],
  "articleBody": " Trans-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease\nAuthors: Yang, G.; Mason, A.; Gill, D.; Schooling, C. M.; Burgess, S.\nScore: 5.9, Published: 2023-09-27 DOI: 10.1101/2023.09.27.23296205\nStructured abstractO_ST_ABSBackgroundC_ST_ABSPlasma low-density lipoprotein (LDL)-cholesterol is positively associated with coronary artery disease risk while biliary cholesterol promotes gallstone formation. ObjectivesWe tested the hypothesis that different plasma LDL-cholesterol lowering pathways have distinct effects on biliary cholesterol and thereby risk of gallstone disease. MethodsThis Mendelian randomization (MR) study used data from the UK Biobank (30,547 gallstone disease cases/336,742 controls), FinnGen (34,461 cases/301,383 controls) and Biobank Japan (9,305 cases/168,253 controls). First, drug-target MR and colocalization analyses were performed to investigate plasma LDL-cholesterol lowering therapies on gallstone disease. Second, clustered MR and pathway analyses were performed to identify distinct mechanisms underlying the association of plasma LDL-cholesterol with gallstone disease. ResultsFor a 1-standard deviation reduction in plasma LDL-cholesterol, genetic mimics of statins were associated with lower risk of gallstone disease (odds ratio 0.72 [95% confidence interval 0.62, 0.83]) but PCSK9 inhibitors and mipomersen were associated with higher risk (1.11 [1.03, 1.19] and 1.23 [1.13, 1.35]). The association for statins was supported by colocalization (posterior probability 98.7%). Clustered MR analyses identified variant clusters showing opposing associations of plasma LDL-cholesterol with gallstone disease, with evidence for ancestry-and sex-specific associations. Among variants predicting lower plasma LDL-cholesterol, those associated with lower risk of gallstone disease were mapped to glycosphingolipid biosynthesis pathway, while those associated with higher risk were mapped to pathways relating to plasma lipoprotein assembly, remodelling, and clearance and ATP-binding cassette transporters. ConclusionsDifferent plasma LDL-cholesterol lowering pathways may have opposing effects on risk of gallstone disease. Notably, statins may reduce risk of gallstone disease. Condensed abstractWe hypothesized that different plasma LDL-cholesterol lowering pathways have distinct effects on risk of gallstone disease. We performed drug-target and clustered Mendelian randomization (MR) analyses, using data from the UK Biobank, FinnGen and Biobank Japan. Genetic mimics of statins were associated with lower risk of gallstone disease, but PCSK9 inhibitors and mipomersen were associated with higher risk. Clustered MR identified variant clusters showing opposing associations of plasma LDL-cholesterol with gallstone disease. This genetic study supports that different plasma LDL-cholesterol lowering pathways have opposing effects on risk of gallstone disease and statins may reduce risk of gallstone disease.\nReal World Experience and Clinical Utility of EsoGuard(R) - Interim Data from the Lucid Registry\nAuthors: Englehardt, R.; Samarasena, J. B.; Bildzukewicz, N. A.; Hamblin, R.; Lee, V. T.; Verma, S.; deGuzman, B. J.; Aklog, L.\nScore: 4.0, Published: 2023-09-27 DOI: 10.1101/2023.09.26.23296162\nBackgroundBarretts Esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC), and guidelines exist for screening, surveillance, and treatment. However, historically most high-risk individuals have not been reliably screened, likely due to a combination of factors associated with patient/physician awareness and use of upper endoscopy (UE) as the traditional screening test. EsoGuard(R) (EG) is a DNA biomarker assay, and EsoCheck(R) (EC) is a non-invasive, swallowable capsule device designed to collect cells from a targeted region of the esophagus. EG and EC in combination offers a well-tolerated, accessible, in-office triage test to improve detection of BE in patients with multiple risk factors. The Lucid Registry captures real-world data from the commercial use of EC with EG, and we present an interim review of clinical utility data from the first 517 enrolled subjects. MethodsMulticenter, prospective, registry designed to capture data from patients undergoing EC cell collection and EG testing in the commercial setting. Data collection consists of demographics, risk factors, test results, provider management, and early clinical outcomes (through a maximum of four months post-EG). This data snapshot includes subjects enrolled from the start of the registry (April 14, 2023), through August 16, 2023. The primary assessment of clinical utility was agreement between EG assay results and physicians decision on whether to refer the patient for subsequent UE. The relationship between BE/EAC risk factors and EG positivity rates was assessed. ResultsAmong 517 subjects enrolled, average age was 47.9{+/-}14.3 years, 47.2% had history of gastroesophageal reflux disease (GERD), and 63.8% had a minimum of 3 established BE risk factors (i.e., met American Gastroenterological Association (AGA) criteria for screening). 58.8% of subjects were firefighters; when firefighting i.e., occupational exposure to smoke and carcinogens is treated as an additional BE/EAC risk factor (+) those of the AGA, 81.2% of the study population had [\u0026ge;]3 risks, making up the \"AGA(+)\" cohort. EG positivity was 14.1%. 437 subjects contributed data for the clinical utility endpoint: agreement between positive EG results and subsequent referral for UE was 100%; agreement between negative EG results and non-referral for UE was 99.4%; concordance between EG results and UE referral decisions was 97.9%. These findings were comparable between the AGA and AGA(+) cohorts. ConclusionsExperience from the Lucid Registry demonstrates that physicians who have adopted EC/EG in the commercial setting are reliably utilizing EG as a triage test to inform decision making on which patients to refer for further endoscopic evaluation of BE.\n",
  "wordCount" : "820",
  "inLanguage": "en",
  "datePublished": "2023-10-04T10:39:33Z",
  "dateModified": "2023-10-04T10:39:33Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/gastroenterology/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      gastroenterology
    </h1>
    <div class="post-meta"><span>updated on October 4, 2023</span>

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.09.27.23296205">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.09.27.23296205" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.09.27.23296205">
        <p class="paperTitle">Trans-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.09.27.23296205" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.09.27.23296205" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Yang, G.; Mason, A.; Gill, D.; Schooling, C. M.; Burgess, S.</p>
        <p class="info">Score: 5.9, Published: 2023-09-27 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.09.27.23296205' target='https://doi.org/10.1101/2023.09.27.23296205'> 10.1101/2023.09.27.23296205</a></p>
        <p class="abstract">Structured abstractO_ST_ABSBackgroundC_ST_ABSPlasma low-density lipoprotein (LDL)-cholesterol is positively associated with coronary artery disease risk while biliary cholesterol promotes gallstone formation.

ObjectivesWe tested the hypothesis that different plasma LDL-cholesterol lowering pathways have distinct effects on biliary cholesterol and thereby risk of gallstone disease.

MethodsThis Mendelian randomization (MR) study used data from the UK Biobank (30,547 gallstone disease cases/336,742 controls), FinnGen (34,461 cases/301,383 controls) and Biobank Japan (9,305 cases/168,253 controls). First, drug-target MR and colocalization analyses were performed to investigate plasma LDL-cholesterol lowering therapies on gallstone disease. Second, clustered MR and pathway analyses were performed to identify distinct mechanisms underlying the association of plasma LDL-cholesterol with gallstone disease.

ResultsFor a 1-standard deviation reduction in plasma LDL-cholesterol, genetic mimics of statins were associated with lower risk of gallstone disease (odds ratio 0.72 [95% confidence interval 0.62, 0.83]) but PCSK9 inhibitors and mipomersen were associated with higher risk (1.11 [1.03, 1.19] and 1.23 [1.13, 1.35]). The association for statins was supported by colocalization (posterior probability 98.7%). Clustered MR analyses identified variant clusters showing opposing associations of plasma LDL-cholesterol with gallstone disease, with evidence for ancestry-and sex-specific associations. Among variants predicting lower plasma LDL-cholesterol, those associated with lower risk of gallstone disease were mapped to glycosphingolipid biosynthesis pathway, while those associated with higher risk were mapped to pathways relating to plasma lipoprotein assembly, remodelling, and clearance and ATP-binding cassette transporters.

ConclusionsDifferent plasma LDL-cholesterol lowering pathways may have opposing effects on risk of gallstone disease. Notably, statins may reduce risk of gallstone disease.

Condensed abstractWe hypothesized that different plasma LDL-cholesterol lowering pathways have distinct effects on risk of gallstone disease. We performed drug-target and clustered Mendelian randomization (MR) analyses, using data from the UK Biobank, FinnGen and Biobank Japan. Genetic mimics of statins were associated with lower risk of gallstone disease, but PCSK9 inhibitors and mipomersen were associated with higher risk. Clustered MR identified variant clusters showing opposing associations of plasma LDL-cholesterol with gallstone disease. This genetic study supports that different plasma LDL-cholesterol lowering pathways have opposing effects on risk of gallstone disease and statins may reduce risk of gallstone disease.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.09.26.23296162">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.09.26.23296162" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.09.26.23296162">
        <p class="paperTitle">Real World Experience and Clinical Utility of EsoGuard(R) - Interim Data from the Lucid Registry</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.09.26.23296162" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.09.26.23296162" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Englehardt, R.; Samarasena, J. B.; Bildzukewicz, N. A.; Hamblin, R.; Lee, V. T.; Verma, S.; deGuzman, B. J.; Aklog, L.</p>
        <p class="info">Score: 4.0, Published: 2023-09-27 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.09.26.23296162' target='https://doi.org/10.1101/2023.09.26.23296162'> 10.1101/2023.09.26.23296162</a></p>
        <p class="abstract">BackgroundBarretts Esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC), and guidelines exist for screening, surveillance, and treatment. However, historically most high-risk individuals have not been reliably screened, likely due to a combination of factors associated with patient/physician awareness and use of upper endoscopy (UE) as the traditional screening test. EsoGuard(R) (EG) is a DNA biomarker assay, and EsoCheck(R) (EC) is a non-invasive, swallowable capsule device designed to collect cells from a targeted region of the esophagus. EG and EC in combination offers a well-tolerated, accessible, in-office triage test to improve detection of BE in patients with multiple risk factors. The Lucid Registry captures real-world data from the commercial use of EC with EG, and we present an interim review of clinical utility data from the first 517 enrolled subjects.

MethodsMulticenter, prospective, registry designed to capture data from patients undergoing EC cell collection and EG testing in the commercial setting. Data collection consists of demographics, risk factors, test results, provider management, and early clinical outcomes (through a maximum of four months post-EG). This data snapshot includes subjects enrolled from the start of the registry (April 14, 2023), through August 16, 2023. The primary assessment of clinical utility was agreement between EG assay results and physicians decision on whether to refer the patient for subsequent UE. The relationship between BE/EAC risk factors and EG positivity rates was assessed.

ResultsAmong 517 subjects enrolled, average age was 47.9{&#43;/-}14.3 years, 47.2% had history of gastroesophageal reflux disease (GERD), and 63.8% had a minimum of 3 established BE risk factors (i.e., met American Gastroenterological Association (AGA) criteria for screening). 58.8% of subjects were firefighters; when firefighting i.e., occupational exposure to smoke and carcinogens is treated as an additional BE/EAC risk factor (&#43;) those of the AGA, 81.2% of the study population had [&amp;ge;]3 risks, making up the &#34;AGA(&#43;)&#34; cohort. EG positivity was 14.1%. 437 subjects contributed data for the clinical utility endpoint: agreement between positive EG results and subsequent referral for UE was 100%; agreement between negative EG results and non-referral for UE was 99.4%; concordance between EG results and UE referral decisions was 97.9%. These findings were comparable between the AGA and AGA(&#43;) cohorts.

ConclusionsExperience from the Lucid Registry demonstrates that physicians who have adopted EC/EG in the commercial setting are reliably utilizing EG as a triage test to inform decision making on which patients to refer for further endoscopic evaluation of BE.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        Â· Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
